Aug 26, 2026
James Sapirstein, CEO of CoCrystal Pharma, is developing a platform of antiviral therapies to treat norovirus, influenza and other viruses. Norovirus, commonly transmitted on cruise ships and in dormitories, currently lacks effective vaccines or treatments. CoCrystal's oral small-molecule approach aims to treat active...
Aug 26, 2026
James Sapirstein, CEO of CoCrystal Pharma, is developing a platform of antiviral therapies to treat norovirus, influenza and other viruses. Norovirus, commonly transmitted on cruise ships and in dormitories, currently lacks effective vaccines or treatments. CoCrystal's oral small-molecule approach aims to treat active...
Aug 3, 2026
Jimmy Chang, Chairman and CEO of TaiMed Biologics, is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an...
Aug 3, 2026
Jimmy Chang, Chairman and CEO of TaiMed Biologics, is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an...
Jul 9, 2026
Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics, has developed a novel class of antimicrobials that operate by disrupting bacterial and fungal cell membranes, rapidly killing the microorganisms. Traditional antimicrobials work by inhibiting bacterial growth, but bacteria have evolved resistance mechanisms against...